Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Solid Biosciences (SLDB) Cash & Current Investments (2017 - 2024)

Solid Biosciences' Cash & Current Investments history spans 8 years, with the latest figure at $171.1 million for Q3 2024.

  • For Q3 2024, Cash & Current Investments rose 19.76% year-over-year to $171.1 million; the TTM value through Dec 2024 reached $50.0 million, down 17.95%, while the annual FY2023 figure was $49.6 million, 76.78% down from the prior year.
  • Cash & Current Investments for Q3 2024 was $171.1 million at Solid Biosciences, down from $190.3 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $268.5 million in Q1 2021 and bottomed at $400000.0 in Q1 2020.
  • The 5-year median for Cash & Current Investments is $167.0 million (2022), against an average of $154.0 million.
  • The largest annual shift saw Cash & Current Investments tumbled 99.58% in 2020 before it soared 67024.25% in 2021.
  • A 5-year view of Cash & Current Investments shows it stood at $154.7 million in 2020, then surged by 34.27% to $207.8 million in 2021, then increased by 2.86% to $213.7 million in 2022, then tumbled by 76.78% to $49.6 million in 2023, then surged by 244.82% to $171.1 million in 2024.
  • Per Business Quant, the three most recent readings for SLDB's Cash & Current Investments are $171.1 million (Q3 2024), $190.3 million (Q2 2024), and $206.1 million (Q1 2024).